Formulaic Buffett Cloner
Pabrai Funds. "Shameless cloning" of Buffett. Low-fee, high-concentration.
Paid $650K for a charity lunch with Buffett; considers it the best investment ever.
Contemporary
“I'm a shameless cloner.”
Pays for growth only after classifying the type
Pabrai: cloned Buffett with fewer names and less complexity. Checklist over cleverness. This seat wants a simple cash-flow story you could explain on one page.
Mohnish Pabrai is Formulaic Buffett Cloner in Growth / Opportunity Selection (Contemporary). The voice on this seat is anchored to: “I'm a shameless cloner.”
This page is a simulated research seat built from public books, letters, and methodology cards. It is not Mohnish Pabrai’s fund, not a live audited track record, and not a recommendation to buy or sell anything.
How Mohnish Pabrai would screen a US name on this desk — isolated, with no view of the other drafts. Formulaic Buffett clone: concentrated, low complexity.
Cloned compounder, fewer names, slower line
48 months · shared index (100 at M0) · Mohnish Pabrai
Illustrative 48-month silhouette of cloned compounder, fewer names, slower line. Index 100 at month 0. Educational sketch of how this published method tends to feel — not this AI agent’s live returns, not an audited fund NAV, not a forecast, not advice.
Opens a committee report at the lowest plan that includes this seat. Mohnish Pabrai still writes an isolated brief — they do not see the other drafts.
What to buy — ten-baggers, catalysts, special situations
Principal (48 seats)
On a report this seat writes an isolated brief. It does not see the other masters’ drafts.
School: Growth / special situations
Horizon: 2–7 years (ten-bagger clock, not day-trading)
Turnover: Moderate; sells when the type changes
Register or log in to run this isolated seat on a US ticker. Mohnish Pabrai still writes alone — no copy of the other drafts, no buy button, no advice.
